Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin

Completed

• Conditions: Meningioma

• Registration Number: NCT04109404
• Lead Sponsor: University Hospital, Brest

Brief Summary

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Detailed Description

Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Study Timeline

• Study Start: 2019-02-25
• Primary Completion: 2019-06-01
• Study Completion: 2019-06-01
• Status Verified: 2019-09
• Study First Submitted: 2019-09-23
• Study First Submitted QC: 2019-09-27
• Study First Posted: 2019-09-30
• Last Update Submitted: 2019-10-10
• Last Update Posted: 2019-10-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• minimum 18 years
• medical follow up in CHRU of Brest
• treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception
• meningioma after treatement by progestin or CYPROTERONE ACETATE

Exclusion Criteria

• history ofbreast cancer
• history of cerebral radiotherapy
• history of neurofibromatosis
• meningioma before treatement by progestin or CYPROTERONE ACETATE
• minor patient

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnosis of meningiomas caracteristics	12 months	meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description

Secondary Outcome Measures

Name	Time	Method
prescription status of progestogenic treatment	12 months	indications, duration of treatment, name and type of treatment

Trial Locations

Locations (1)

Département de Nutrition - CHRU de Brest; 🇫🇷 Brest, France